Bristol Myers Squibb to Report Results for Fourth Quarter 2021 on February 4, 2022 Pharmaceutical Investing
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma Following Surgery Pharmaceutical Investing
Daiichi Sankyo Authorizes the First YESCARTA® CAR T-cell Therapy Treatment Site in Japan Pharmaceutical Investing
Merck and Ridgeback Announce Publication of Phase 3 Study of Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, in the New England Journal of Medicine Pharmaceutical Investing
EMA Issues Advice for Potential Early Use of Pfizer's Novel COVID-19 Oral Antiviral Candidate Pharmaceutical Investing
ADDING and REPLACING European Commission Approves Merck's VAXNEUVANCE for Individuals 18 Years of Age and Older Pharmaceutical Investing
Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine Pharmaceutical Investing
European Commission Approves Merck's VAXNEUVANCE for Individuals 18 Years of Age and Older Pharmaceutical Investing
Arena Pharmaceuticals INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arena Pharmaceuticals, Inc. - ARNA Life Science Investing
BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States Pharmaceutical Investing
Seegnal Inc. Establishes Strategic Commercialization Team and Appoints Arx as Investor Relations Advisor
